1
|
Guo W, Yang Z, Wang K, Li W, Zhao Y, Yang Y, Chang W, Gong Z, Liu Z, Chen Y, Li Q. Discovery of Unique Bis-Substituted Aromatic Amide Derivatives as Novel Highly Potent Antibiotics for Combating Methicillin-Resistant Staphylococcus aureus (MRSA). J Med Chem 2024; 67:2129-2151. [PMID: 38289145 DOI: 10.1021/acs.jmedchem.3c02064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2024]
Abstract
Due to the increasing antibiotic resistance, developing novel antimicrobials to fight infections caused by resistant bacteria is imperative. Herein, a series of novel bis-substituted aromatic amides were designed and synthesized through modifying the hit compound 1, and their antimicrobial activities were evaluated. Among them, compound 4t, as the most potent lead, exhibited excellent antimicrobial activities against Gram-positive bacteria, including clinical methicillin-resistant Staphylococcus aureus (MRSA) isolates, while keeping weak hemolytic and mammalian cytotoxic activities. Furthermore, compound 4t displayed rapid bactericidal capabilities, low tendency to produce resistance, and favorable capacities to destroy bacterial biofilms. Further explorations indicated that compound 4t induces bacterial death by binding to cardiolipin (CL) on the bacterial membrane, disrupting the cell membrane, and facilitating the accumulation of reactive oxygen species (ROS). Additionally, compound 4t showed remarkable anti-MRSA activity in vivo, demonstrating compound 4t could be developed as a potential candidate to combat MRSA infections.
Collapse
Affiliation(s)
- Weikai Guo
- The Jointed National Laboratory of Antibody Drug Engineering, Henan University, Kaifeng 475004, China
| | - Zhengfan Yang
- The Jointed National Laboratory of Antibody Drug Engineering, Henan University, Kaifeng 475004, China
| | - Kexiao Wang
- The Jointed National Laboratory of Antibody Drug Engineering, Henan University, Kaifeng 475004, China
| | - Wenyu Li
- The Jointed National Laboratory of Antibody Drug Engineering, Henan University, Kaifeng 475004, China
| | - Yanyang Zhao
- The Jointed National Laboratory of Antibody Drug Engineering, Henan University, Kaifeng 475004, China
| | - Yuqing Yang
- The Jointed National Laboratory of Antibody Drug Engineering, Henan University, Kaifeng 475004, China
| | - Wenjing Chang
- Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450003, China
| | - Zhen Gong
- Department of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China
| | - Zhou Liu
- Department of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China
| | - Yihua Chen
- Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China
| | - Qiming Li
- The Jointed National Laboratory of Antibody Drug Engineering, Henan University, Kaifeng 475004, China
| |
Collapse
|
2
|
Di Marco CN, Terrell L, Sanchez R, Rueda L, Shuster L, Nartey EN, McHugh C, Mack JF, Shu A, Tian X, Medina JR, Rivero R, Manetsch R, Heerding D, Mangatt B. Design and synthesis of aminopyridine containing biaryls reducing c-MYC protein levels in cells. Bioorg Med Chem Lett 2023; 92:129385. [PMID: 37339719 DOI: 10.1016/j.bmcl.2023.129385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Accepted: 06/16/2023] [Indexed: 06/22/2023]
Abstract
The c-MYC oncogene transcription factor has been implicated in cell cycle regulation controlling cell growth and proliferation. It is tightly regulated in normal cells, but has been shown to be deregulated in cancer cells, and is thus an attractive target for oncogenic therapies. Building upon previous SAR, a series of analogues containing benzimidazole core replacements were prepared and evaluated, leading to the identification of imidazopyridazine compounds that were shown to possess equivalent or improved c-MYC HTRF pEC50 values, lipophilicity, solubility, and rat pharmacokinetics. The imidazopyridazine core was therefore determined to be superior to the original benzimidazole core and a viable alternate for continued lead optimization and medicinal chemistry campaigns.
Collapse
Affiliation(s)
- Christina N Di Marco
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA; Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA.
| | - Lamont Terrell
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Robert Sanchez
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Lourdes Rueda
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Leanna Shuster
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | | | - Charles McHugh
- Drug Metabolism and Pharmacokinetics, Research In Vivo/In Vitro Translation, GSK, Collegeville, PA 19426, USA
| | - James F Mack
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Arthur Shu
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Xinrong Tian
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Jesus R Medina
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Ralph Rivero
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Roman Manetsch
- Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA; Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, USA; Center for Drug Discovery, Northeastern University, Boston, MA 02115, USA; Barnett Institute of Chemical and Biological Analysis, Northeastern University, Boston, MA 02115, USA
| | - Dirk Heerding
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| | - Biju Mangatt
- Medicinal Science and Technology, GSK, Collegeville, PA 19426, USA
| |
Collapse
|
3
|
Plater MJ, Harrison WTA. Reactions of 4,5-difluoro-1,2-dinitrobenzene with amines in dimethylformamide or EtOH. JOURNAL OF CHEMICAL RESEARCH 2023. [DOI: 10.1177/17475198231154812] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Substitution reactions of 1,2-difluoro-4,5-dinitrobenzene were explored in dimethylformamide alone and with KOH/H2O, Hünig’s base or Et3N and with Me2NHCl/Et3N in EtOH. The fluorine atoms were always displaced in preference to the nitro groups. Three compounds were prepared from these studies and were characterised by X-ray single crystal structure determinations.
Collapse
Affiliation(s)
- M John Plater
- Department of Chemistry, University of Aberdeen, Aberdeen, UK
| | | |
Collapse
|